Although current therapeutic approaches, such as the use of NF-κB or IKK-β inhibitors, could potentially abrogate the cancer-promoting activities of NF-κB, they fail to preserve its pleiotropic physiological functions in normal cells, such as functions in immunity and inflammation [18, 20] Therefore, there is an urgent need to identify more effective therapeutic targets that regulate NF-κB in an appropriate manner as an alternative to global NF-κB blockade. The gene discussed is NFKB1; the disease is cancer.